ResearcherUniversity of TwenteActive in the last 2 years

Kunal P. Pednekar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7134-1721; OpenAlex author ID A5007667206. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.apsb.2025.10.022 ↗
Novel 3D µtissues Mimicking the Fibrotic Stroma in Pancreatic Cancer to Study Cellular Interactions and Stroma-Modulating Therapeutics. Co-author DOI 10.3390/cancers13195006 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jai Prakash · 2 shared papers, 2021–2026 · strength 0.49
- Paper Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in p… DOI 10.1016/j.apsb.2025.10.022 ↗
- Paper Novel 3D µtissues Mimicking the Fibrotic Stroma in Pancreatic Cancer to Study Cellular Interactions and Stroma-Modulati… DOI 10.3390/cancers13195006 ↗
Praneeth Reddy Kuninty · 1 shared paper, 2026 · strength 0.30
- Paper Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in p… DOI 10.1016/j.apsb.2025.10.022 ↗
Deby Fajar Mardhian · 1 shared paper, 2026 · strength 0.30
- Paper Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in p… DOI 10.1016/j.apsb.2025.10.022 ↗
Jennifer P. Morton · 1 shared paper, 2026 · strength 0.30
- Paper Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in p… DOI 10.1016/j.apsb.2025.10.022 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.